Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences AmBisome (liposomal amphotericin B by Quarter
AmBisome (liposomal amphotericin B — systemic antifungal) ($M) ($M)
Gilead Sciences AmBisome (liposomal amphotericin B: $110M in Q2 2026, down 14.7% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-06) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up amBisome (liposomal amphotericin B
Cite this data
StockData. (2026). Gilead Sciences AmBisome (liposomal amphotericin B ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other-ambisome
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.